Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 484

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis

Open access
Dellon, Evan S., Rothenberg, Marc E., Collins, Margaret H., Hirano, Ikuo, Chehade, Mirna, Bredenoord, Albert J., Lucendo, Alfredo J., Spergel, Jonathan M., Aceves, Seema, Sun, Xian, Kosloski, Matthew P., Kamal, Mohamed A., Hamilton, Jennifer D., Beazley, Bethany, McCann, Eilish, Patel, Kiran, Mannent, Leda P., Laws, Elizabeth, Akinlade, Bolanle, Amin, Nikhil, Lim, Wei Keat, Wipperman, Matthew F., Ruddy, Marcella, Patel, Naimish, Weinreich, David R., Yancopoulos, George D., Shumel, Brad, Maloney, Jennifer, Giannelou, Angeliki, Shabbir, Arsalan·2022·New England Journal of Medicine

Abstract

BACKGROUND: Dupilumab, a fully human monoclonal antibody, blocks interleukin-4 and interleukin-13 signaling, which have key roles in eosinophilic esophagitis. METHODS: We conducted a three-part, phase 3 trial in which patients 12 years of age or older underwent randomization in a 1:1 ratio to receive subcutaneous dupilumab at a weekly dose of 300 mg or placebo (Part A) or in a 1:1:1 ratio to receive 300 mg of dupilumab either weekly or every 2 weeks or weekly placebo (Part B) up to week 24. Eligible patients who completed Part A or Part B continued the trial in Part C, in which those who completed Part A received dupilumab at a weekly dose of 300 mg up to week 52 (the Part A-C group); Part C that included the eligible patients from Part B is ongoing. The two primary end points at week 24 were histologic remission (≤6 eosinophils per high-power field) and the change from baseline in the Dysphagia Symptom Questionnaire (DSQ) score (range, 0 to 84, with higher values indicating more frequent or more severe dysphagia). RESULTS: In Part A, histologic remission occurred in 25 of 42 patients (60%) who received weekly dupilumab and in 2 of 39 patients (5%) who received placebo (difference, 55 percentage points; 95% confidence interval [CI], 40 to 71; P<0.001). In Part B, histologic remission occurred in 47 of 80 patients (59%) with weekly dupilumab, in 49 of 81 patients (60%) with dupilumab every 2 weeks, and in 5 of 79 patients (6%) with placebo (difference between weekly dupilumab and placebo, 54 percentage points; 95% CI, 41 to 66 [P<0.001]; difference between dupilumab every 2 weeks and placebo, 56 percentage points; 95% CI, 43 to 69 [not significant per hierarchical testing]). The mean (±SD) DSQ scores at baseline were 33.6±12.41 in Part A and 36.7±11.22 in Part B; the scores improved with weekly dupilumab as compared with placebo, with differences of -12.32 (95% CI, -19.11 to -5.54) in Part A and -9.92 (95% CI, -14.81 to -5.02) in Part B (both P<0.001) but not with dupilumab every 2 weeks (difference in Part B, -0.51; 95% CI, -5.42 to 4.41). Serious adverse events occurred in 9 patients during the Part A or B treatment period (in 7 who received weekly dupilumab, 1 who received dupilumab every 2 weeks, and 1 who received placebo) and in 1 patient in the Part A-C group during the Part C treatment period who received placebo in Part A and weekly dupilumab in Part C. CONCLUSIONS: Among patients with eosinophilic esophagitis, subcutaneous dupilumab administered weekly improved histologic outcomes and alleviated symptoms of the disease. (Funded by Sanofi and Regeneron Pharmaceuticals; ClinicalTrials.gov number, NCT03633617.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa2205982

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Cited by

See all 484

Metadata

Authors
Dellon, E. S., Rothenberg, M. E., Collins, M. H., Hirano, I., Chehade, M., Bredenoord, A. J., Lucendo, A. J., Spergel, J. M., Aceves, S., Sun, X., Kosloski, M. P., Kamal, M. A., Hamilton, J. D., Beazley, B., McCann, E., Patel, K., Mannent, L. P., Laws, E., Akinlade, B., Amin, N., Lim, W. K., Wipperman, M. F., Ruddy, M., Patel, N., Weinreich, D. R., Yancopoulos, G. D., Shumel, B., Maloney, J., Giannelou, A., & Shabbir, A.
Venue
New England Journal of Medicine
Published
2022-12-22
Volume
387
Issue
25
Pages
2317-2330
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4313237193
Cited by
484
References
24
FWCI
82.45
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis. https://app.cochat.ai/papers/10.1056/nejmoa2205982
The paper
Dellon, E. S., Rothenberg, M. E., Collins, M. H., Hirano, I., Chehade, M., Bredenoord, A. J., Lucendo, A. J., Spergel, J. M., Aceves, S., Sun, X., Kosloski, M. P., Kamal, M. A., Hamilton, J. D., Beazley, B., McCann, E., Patel, K., Mannent, L. P., Laws, E., Akinlade, B., . . . Shabbir, A. (2022). Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2205982

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.